Study record
The role of FPR2-mediated ferroptosis in formyl peptide-induced acute lung injury against endothelial barrier damage and protective effect of the mitochondria-derived peptide MOTS-c
Wen Z, Fan J, Zhan F et al. · Int Immunopharmacol · 2024
AnimalMOTS-c administeredEvidence tier CAlso: Cell study (in vitro)
What this study reported
Reported that fMLP promoted ferroptosis and endothelial barrier disruption in rat lungs and in human pulmonary microvascular endothelial cells, and that MOTS-c was associated with less ferroptosis and with lower inflammatory and oxidative stress markers through Nrf2 and MAPK signalling.
Limitations
Single acute injury model with group sizes and blinding not reported; the mechanism rests on FPR2 knockdown and inhibitors in one endothelial cell line; rodent and cell findings do not transfer to people.
Study record
| Study model | Animal study (in vivo) |
|---|---|
| Substance studied | MOTS-c administeredSynthetic MOTS-c was given to cells, animals or people. |
| Species | rat, human |
| System studied | Rats with fMLP-induced acute lung injury and human pulmonary microvascular endothelial cells |
| Population | Not reported |
| Design | Controlled animal experiment with cell culture experiments |
| Sample size as reported | Not reported |
| Control group | fMLP-exposed rats and cells not given MOTS-c |
| Route (data field only) | Not reported |
| Endpoints measured | lung histopathology; inflammatory and oxidative stress markers; ferroptosis-related proteins; endothelial barrier proteins; Nrf2 and MAPK signalling |
| Pathways measured | NRF2 / antioxidant response · MAPK signalling · Oxidative stress · Inflammation |
| Research areas | Lung · Inflammation & immunity |
| Evidence tier | C — Animal in vivo |
| Publication types | Journal Article |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Direct
- Model applicability
- Mammalian
- Sample size
- Not reported
- Controls
- Appropriate
- Outcome validity
- Surrogate
- Support for its own conclusion
- Moderate
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.